Subject:
Biology And Life Sciences,
Immunology And Microbiology
Keywords:
L-arginase; bacterial; molecular detection; anticancer; auxotrophic.
Online: 1 August 2024 (12:10:25 CEST)
Background: The World Health Organization identifies lung and prostatic cancers as solid tumors with significant global lethality, both being auxotrophic cancers for L-arginine aminoacid. The aim of the study: The study aims to detect L-arginase-expressing bacteria from various soil environments in Egypt using 16S rRNA and characterize its anticancer activity. Methodology: A hundred samples of Egyptian grassland soil were gathered at a depth of 11–20 cm, close to wheat mills. Using fast plate assay screening and spectrophotometric analysis, the presence of bacteria generating L-arginase was verified. The major soil bacterial isolates were identified by morphological characterization, biochemical responses, and 16SrRNA sequencing methods. The anticancer activity of the test enzyme was assessed using MTT assay. Results: On the MAA medium, only the bacterial isolates capable of using L-arginine as the only metabolic source for carbon and nitrogen were cultivated. Bacillus cereus DSM 360 was shown to be the prevailing bacterial isolate generating L-arginase using molecular detection and biochemical reactions. When Co+2, Ni+2, and Mn+2 metal ions were present as co-factors, bacterial L-arginase demonstrated remarkable anticancer action against auxotrophic tumors for L-arginine. The total protein content was 0.349 mg, while total enzyme activity was 8.174 U with 61% enzyme recovery. As well as the specific activity reached 23.4212 U/mg. Using the mass spectrometer, the molecular weight of the bacterial L-arginase was revealed to be 37 KDa. The bacterial L-arginase's IC50 values were 3.12 U/ml for the lung cancer cell line, 3.91 U/ml for prostatic cancer cell line, 0.91 U/ml for acute promyelocytic leukemia cancer cell line and 2.73 U/ml for kidney cancer cell line. The enzyme under test showed kinetic characteristics of 7.36 mmol/l and 6.14 μmol/min for Km and Vmax, respectively. The half-life time (T1/2) was 90.17 min at 50°С, while being 86.53 min at 60°С. The test enzyme was thermostable at 60°С for 1 hour. Conclusion: The study showed a potential strategy by identifying and determining a newly discovered bacterial L-arginase enzyme as an anticancer agent in Egypt's soil settings.
Subject:
Biology And Life Sciences,
Immunology And Microbiology
Keywords:
L‐glutaminase; Acute lymphocytic leukaemia; Breast cancer; Auxotrophic
Online: 9 August 2024 (07:25:48 CEST)
Background:
Breast cancer and other neoplasms, such as acute lymphocytic leukaemia, are a
severe hazard to public health globally. L-glutamine-degrading enzymes are required
for the treatment of malignancies such as acute lymphocytic leukemia and breast
cancer. L-glutaminase, an amidohydrolase, has been shown to be an effective
chemotherapeutic tool for treating a variety of malignancies. The aim of the study:
Molecular characterization is used in the study and production of bacterial L- glutaminase as an anticancer agent from a variety of Egyptian soil locales. The type of the study:
Screening experimental study. Methodology:
In the current study, many bacterial isolates were tested on mineral L-glutamine
agar selective medium (MGA) to evaluate if they generated L-glutaminase. The most
effective positive bacterial isolates that produce L-glutaminase, however, were
discovered by morphological and biochemical analysis. The primary positive isolate
producing L-glutaminase was also identified utilizing molecular detection by 16S
rRNA sequencing homology technique. The properties of bacteria-produced L- glutaminase were investigated. The anticancer activity was assessed with an MTT
assay. Results:
Sole bacterial isolates that only needed L-glutamine for metabolic nitrogen grew well
on MGA. The optimal conditions for producing positive bacterial isolates were pH 7.4
and 37 ̊C. The morphological and biochemical investigations of soil samples from
diverse soil conditions in Egypt revealed that Bacillus subtilis subsp. niger (ATCC 9372)
was the primary positive bacterial isolate producing L-glutaminase. At a pH of 7.4
and a temperature of 37 °C, the activators KCL, ZnSO4, FeSO4, K2HPO4, and MgSO4
offered ideal conditions for defining L-glutaminase production. L-glutaminase from
Bacillus subtilis was detected to be a highly bioavailable and efficient anticancer
treatment. The original yield [productivity] from MGA was 6.3 U/ml, but invitro coupled
transcription and translation production raised it to 89± 1 U/ml. L-glutaminase had a
molecular mass of approximately 36 kDa. The purification of L-glutaminase resulted
total activity of 21,883 ± 15.67 (U), specific activity of 379.14 ± 7.35 (U/mg of
protein), and purification fold of 1.82 ± 3.06. The enzymatic activators Ni2+ and Mg
2+
increased L-glutaminase activity by 20%, 27%, respectively. The compound showed significant anticancer activity (IC50 = 38.72, 8.6, 6.41, 19.02, 49.83, and 9.45 μg/ml) against cancer cell lines from the liver (HepG-2), colon (HCT- 116), breast (MCF-7), lung (A-549), lymphocytic (CCL-120), and cervical (Hela). The kinetic parameters Km and Vmax were 15.2^ 10
-3 M and 119.86 μmol/ml/min,
indicating a higher affinity for the substrate. The enzyme demonstrated high efficacy at pH 6.5 and temperature 35. The enzyme
was thermostable at 58 ̊C for 1 hour.
Conclusion:
Acute lymphocytic leukemia and breast cancer are two instances of auxotrophic
malignancies for which L-glutamine is the sole metabolic source, and Bacillus subtilis- derived L-glutaminase was a suitable enzyme in their treatment.
Subject:
Medicine And Pharmacology,
Medicine And Pharmacology
Keywords:
L-glutaminase; Acute lymphocytic leukaemia; Breast cancer; Auxotrophic
Online: 16 May 2024 (11:55:34 CEST)
Background:
Breast cancer and other neoplasms like acute lymphocytic leukemia pose a serious threat to public health worldwide. Treatment for malignancies including acute lymphocytic leukemia and breast cancer requires enzymes that break down L-glutamine. An amidohydrolase called L-glutaminase can be an effective chemotherapeutic tool for treating various cancers.
Methods:
On mineral L-glutamine agar selective medium (MGA), a few bacterial isolates were examined in the current investigation to see if they produced L-glutaminase. However, the most effective positive bacterial isolates generating L-glutaminase were identified using morphological and biochemical testing. Molecular detection using the direct Southern blotting approach was also used to determine the main positive isolate that produces L-glutaminase. L-glutaminase synthesis by bacteria was evaluated for its characteristics. Using an MTT test, the anticancer activity was evaluated.
Results:
exclusive bacterial isolates that used L-glutamine as their sole source of metabolic nitrogen exhibited favorable growth on MGA. PH 7.4 and a temperature of 37 0C were the ideal environmental and physiological conditions for developing positive bacterial isolates. From the soil samples taken from various soil conditions in Egypt, the morphological and biochemical analyses showed that Bacillus cereus 14579 was the main positive bacterial generating L-glutaminase isolate. At a pH of 7.4 and a temperature of 37 °C, the following activators—KCL, ZnSO4, FeSO4, K2HPO4, and MgSO4—provided the high-grade circumstances for characterizing L-glutaminase synthesis. Bacillus cereus-produced L-glutaminase has shown excellent bioavailability and effectiveness as an anticancer therapy.
The yield [productivity] was 5.2 U/ml during the original manufacture from MGA, but it increased to 42.96 U/ ml by bacterial recombinant DNA manufacturing. The molecular mass of L-glutaminase was roughly 37 KDa. L-glutaminase was purified, yielding final enzyme recovery of 55 1.23%, total activity 12,990± 19.76 ( U), specific activity 384.66± 8.92( U/ mg of protein), and purification fold 2± 2.99. Furthermore, the L-glutaminase activity was raised by 19%, 23%, 15%, and 9%, respectively, by the enzymatic activators Mn2+, K+, Na+, and Fe3+. It demonstrated strong DPPH scavenging activity (IC50 = 61 μg/ mL) and anticancer activity( IC50 = 40.72, 9.7, 7.39, 20.61, 51.28, and 11.55 μg/ mL, respectively) against human liver (HepG-2), colon ( HCT-116), breast ( MCF-7), lung( A-549), lymphocytic( CCL-120), and cervical( Hela) cancer cell lines. A stronger affinity for its substrate was shown by the kinetic parameters of Km and Vmax, which were 13.2 10-5 M and 119.86 μmol/ ml/ min, respectively.
Conclusion:
Acute lymphocytic leukemia and breast cancer are examples of auxotrophic malignancies for which L-glutamine serves as the only metabolic source, and L-glutaminase generated by Bacillus cereus was an appropriate enzyme in the therapy of these diseases.